We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01517529
Recruitment Status : Completed
First Posted : January 25, 2012
Results First Posted : September 30, 2015
Last Update Posted : November 20, 2015
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The major goal of this project is to identify the role of the immune responses in the emergence of protease inhibitor mutants during therapy.

Condition or disease
Hepatitis C

Detailed Description:

Objective 1: Evaluate the role of the immune responses in determining the emergence of HCV NS3 resistance mutation during protease inhibitor therapy

Hypothesis 1 (HT 1): Low HLA binding to peptides containing protease inhibitor resistance mutations is associated with the emergence of protease inhibitor mutants during therapy and failure of the treatment.

Hypothesis 2 (HT 2): A hole in T cell repertoire may allow emergence of protease inhibitor mutants during protease inhibitor therapy which leads to loss of the immune responses to these mutants and failure of treatment.


Study Design

Study Type : Observational
Actual Enrollment : 10 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Evaluating the Role of the Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy
Study Start Date : January 2012
Primary Completion Date : July 2014
Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Group/Cohort
10 Hepatitis C infected subjects
10 chronically HCV-infected patients who fail the standard peg-IFN and Ribavirin therapy (NR) and are therefore eligible for combined treatment with Protease Inhibitor therapy.


Outcome Measures

Primary Outcome Measures :
  1. Number of Participants Who Completed Standard Treatment [ Time Frame: 9 months ]
    Blood samples will be drawn while the subject is on treatment to measure viral load and HCV-specific immune responses.


Secondary Outcome Measures :
  1. Number of Participants Who Cleared the Virus [ Time Frame: 9 months ]
    Blood samples will be drawn while the subject is on treatment to measure viral load and HCV-specific immune responses


Biospecimen Retention:   Samples With DNA
Blood lymphocytes from enrolled subjects will be retained until all investigations will be performed and publications are generated. After that remaining samples will be discarded properly according to the Biosafety instructions.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Investigators plan to enroll 20 human subjects with chronic hepatitis C virus infection from the outpatient clinic at the University of Cincinnati College of Medicine.
Criteria

Inclusion Criteria: All chronically HCV-infected patients who fail peg-IFN and RBV therapy and are eligible for combined treatment with PI therapy will be enrolled. Briefly, this includes:

  1. Male or female
  2. Age 18 to 65
  3. Chronic HCV infection evidenced by liver biopsy or persistent HCV viremia for >6 months
  4. Treatment experienced and classified as non-responder or relapser to prior interferon-based therapy.

Exclusion criteria:

  1. Treatment naïve chronically HCV-infected patients.
  2. Patients with a history of inflammatory bowel diseases (IBD) or suspected IBD, autoimmune diseases, including rheumatoid arthritis, and any patients on systemic immunomodulators.
  3. Pregnancy
  4. HIV
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01517529


Locations
United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45267
Sponsors and Collaborators
University of Cincinnati
Merck Sharp & Dohme Corp.
Investigators
Principal Investigator: Mohamed Tarek. M Shata, MD, PhD University of Cincinnati
More Information

Responsible Party: Mohamed Tarek Shata, Principal investigator, University of Cincinnati
ClinicalTrials.gov Identifier: NCT01517529     History of Changes
Other Study ID Numbers: UC 11101915
First Posted: January 25, 2012    Key Record Dates
Results First Posted: September 30, 2015
Last Update Posted: November 20, 2015
Last Verified: October 2015

Keywords provided by Mohamed Tarek Shata, University of Cincinnati:
Hepatitis C
HCV

Additional relevant MeSH terms:
Hepatitis
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Flaviviridae Infections
RNA Virus Infections
Protease Inhibitors
HIV Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents